87.5% of evaluable subjects exhibited clinical benefit, including 2 complete responses and 3 partial responses
All patients tested were positive for survivin and blood analysis shows strong survivin-specific T cell responses correlated with clinical responses
The final conference poster presentation will include additional data collected between the abstract submission and the presentation itself
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--Nov. 6, 2019-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that updated results from SPiRel, a Phase 2 study of the Company’s lead program, DPX-Survivac, as a combination therapy in patients with recurrent/refractory diffuse large B-cell lymphoma (DLBCL), will be featured in a poster session at the 61stAmerican Society of Hematology (ASH) Annual Meeting, being held December 7-10, 2019 in Orlando, FL.
Poster Presentation Details:
Poster Title: Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The SPiReL Study
Presenter: Neil Berinstein, MD, FRCPC, ABIM, Haematologist at the Sunnybrook Health Sciences Centre, Toronto, ON.
Publication Number: 3236
Session Name: 704. Immunotherapies: poster II
Date and Time: December 8, 2019, 6:00 p.m. – 8:00 p.m. EDT
Location: Orange County Convention Center, Hall B
The American Society of Hematology has published the official abstracts on its meeting website in advance of the ASH Annual Meeting.
The final conference poster presentation will include additional data collected between the abstract submission on June 27, 2019 and the presentation itself. The poster will be available under Events, Webcasts and Presentations in the investors section of IMV’s website on the day of presentation.
About the SPiReL study
“SPiReL” is a Phase 2 non-randomized, open label, efficacy and safety study. Eligible subjects have recurrent/refractory DLBCL, confirmed expression of survivin are eligible for curative therapy. Study treatment includes administering two doses of 0.5 mL of DPX-Survivac 3 weeks apart followed by up to six 0.1 mL doses every 8 weeks. Intermittent low dose cyclophosphamide is administered orally at 50 mg twice daily for 7 days followed by 7 days off. Pembrolizumab 200 mg is administered every 3 weeks. Study participants continue active therapy for up to one year or until disease progression, whichever occurs first.
The primary objective of this study is to document the response rate to this treatment combination using modified